GeneoDx secures nearly RMB 200M in funding to sustain focus on IVD technological innovation and industrial transformation

Recently, Shanghai GeneoDx Biotech ("GeneoDx") has successfully completed a new round of financing. This round attracted investments from several prominent institutions, including Huagai Capital. Concurrently, the original controlling shareholder increased its capital investment. The state-owned shareholding ratio remains at 51%. This infusion of capital will provide strong momentum for GeneoDx in key strategic areas such as executing industrial mergers and acquisitions, iterating and upgrading core technologies, and expanding its market presence both domestically in China and internationally.

As a globally leading technology industrialization and transformation platform in the IVD (in vitro diagnostics) field, GeneoDx, through continuous innovation in infectious disease and tumor diagnostics, has established a product portfolio with significant differentiated advantages. The core products of GeneoDx include:

DNA Methylation Detection Kit for Human ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 Genes -- Cervical Cancer: The first cervical cancer gene methylation detection kit in China. It assists colposcopic biopsy diagnosis at the genetic level, evaluates cancer risk, and helps clinicians manage treatment choices, truly enabling "earlier detection and better treatment."

Multiplex Nucleic Acid Detection Kit for Respiratory Pathogens: A 16-plex detection kit capable of simultaneously detecting 16 pathogens, addressing challenges in pathogen identification and mixed infection detection. It is currently one of the respiratory nucleic acid detection products available in China with the highest number of detectable pathogens.

Multiplex Nucleic Acid Detection Kit for Encephalitis/Meningitis Pathogens: The first Class III medical device registration certificate issued by China's National Medical Products Administration (NMPA) to a Chinese enterprise for the auxiliary diagnosis of central nervous system infections (encephalitis/meningitis), facilitating rapid diagnosis of CNS infections.

Treponema pallidum Triple Detection Kit (TP3): The first nucleic acid co-detection product for Treponema pallidum and Herpes Simplex Virus Type I/II in China, and also the first approved nucleic acid detection kit for Treponema pallidum in China. When used in conjunction with the Multiplex Nucleic Acid Detection Kit for Urogenital Tract Infection Pathogens (STD6), it covers the main pathogens of urogenital tract infections, offering high clinical diagnostic value.

Pneumocystis jirovecii Nucleic Acid Detection Kit: Overcomes the limitations of traditional microscopy and serological testing regarding time-to-result, environmental requirements, and operator skill. It offers high sensitivity and specificity, playing a significant role in improving the early diagnosis and treatment of Pneumocystis pneumonia, guiding precise clinical medication, reducing complications, and lowering mortality rates.

Leveraging the technological leadership, clinical utility of its products, and the resource synergy with its controlling shareholder, GeneoDx's marketing network has expanded to cover major top-tier hospitals, Centers for Disease Control and Prevention (CDCs), and Inspection and Quarantine institutions across China, establishing a stable and highly engaged core customer base.